- Home
- NEN vs ENGN Comparison
NEN vs ENGN Comparison
Compare NEN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- ENGN
- Stock Information
- Founded
- NEN 1977
- ENGN 1999
- Country
- NEN United States
- ENGN Canada
- Employees
- NEN N/A
- ENGN N/A
- Industry
- NEN Building operators
- ENGN
- Sector
- NEN Real Estate
- ENGN
- Exchange
- NEN Nasdaq
- ENGN Nasdaq
- Market Cap
- NEN 282.1M
- ENGN 317.6M
- IPO Year
- NEN N/A
- ENGN N/A
- Fundamental
- Price
- NEN $82.70
- ENGN $6.97
- Analyst Decision
- NEN
- ENGN Strong Buy
- Analyst Count
- NEN 0
- ENGN 9
- Target Price
- NEN N/A
- ENGN $29.78
- AVG Volume (30 Days)
- NEN 7.4K
- ENGN 108.9K
- Earning Date
- NEN 01-01-0001
- ENGN 03-10-2025
- Dividend Yield
- NEN 1.98%
- ENGN N/A
- EPS Growth
- NEN 67.91
- ENGN N/A
- EPS
- NEN 3.91
- ENGN N/A
- Revenue
- NEN $81,169,352.00
- ENGN N/A
- Revenue This Year
- NEN N/A
- ENGN N/A
- Revenue Next Year
- NEN N/A
- ENGN N/A
- P/E Ratio
- NEN $20.71
- ENGN N/A
- Revenue Growth
- NEN 10.81
- ENGN N/A
- 52 Week Low
- NEN $67.19
- ENGN $4.42
- 52 Week High
- NEN $84.00
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- NEN 53.23
- ENGN 46.21
- Support Level
- NEN $80.88
- ENGN $6.32
- Resistance Level
- NEN $82.74
- ENGN $8.40
- Average True Range (ATR)
- NEN 0.02
- ENGN 1.03
- MACD
- NEN 0.03
- ENGN 0.01
- Stochastic Oscillator
- NEN 85.28
- ENGN 37.71
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.